Anti-EGFR strategy for colorectal cancer: Searching for the real target

被引：0
|
作者：
Zaniboni, A. [1 ]
Meriggi, F. [1 ]
机构：
[1] Fdn Poliambulanza, UO Oncol Med, I-25100 Brescia, Italy
来源：
LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 08期
关键词：
cetuximalb; colorectal cancer; anti-EGFR therapy;
D O I：
10.2174/157018006778194673
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable.
引用
收藏
页码：541 / 543
页数：3
相关论文
共 50 条
  • [21] Real-World Outcomes of Anti-EGFR Rechallenge Guided by Liquid Biopsy in Metastatic Colorectal Cancer
    Roque, Ricardo
    Santos, Rita Antunes
    Santos, Luis Guilherme
    Coelho, Rita
    Fernandes, Isabel Viera
    Cunha, Goncalo
    Goncalves, Marta
    Paulo, Judy
    Bonito, Nuno
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2025,
  • [22] EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
    Okada, Yasuyuki
    Kimura, Tetsuo
    Nakagawa, Tadahiko
    Okamoto, Koichi
    Fukuya, Akira
    Goji, Takahiro
    Fujimoto, Shota
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Tsuji, Yasushi
    Okahisa, Toshiya
    Takayama, Tetsuji
    MOLECULAR CANCER RESEARCH, 2017, 15 (10) : 1445 - 1454
  • [23] Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer
    Cripps, C.
    Gill, S.
    Ahmed, S.
    Colwell, B.
    Dowden, S.
    Kennecke, H.
    Maroun, J.
    Samson, B.
    Thirlwell, M.
    Wong, R.
    CURRENT ONCOLOGY, 2010, 17 (06) : 272 - 278
  • [24] Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories
    Cheng, Lei
    Ren, Wei
    Xie, Li
    Li, Ming
    Liu, Jiang
    Hu, Jing
    Liu, Bao-Rui
    Qian, Xiao-Ping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 1 - 13
  • [25] Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
    F Di Fiore
    R Sesboüé
    P Michel
    J C Sabourin
    T Frebourg
    British Journal of Cancer, 2010, 103 : 1765 - 1772
  • [26] Panitumumab: A new anti-EGFR antibody for the treatment of advanced colorectal cancer
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2006, 6 (01) : 13 - 13
  • [27] Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives
    Boeckx, Nele
    Op de Beeck, Ken
    Deschoolmeester, Vanessa
    Van Camp, Guy
    Pauwels, Patrick
    Peeters, Marc
    CURRENT COLORECTAL CANCER REPORTS, 2014, 10 (04) : 380 - 394
  • [28] Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer
    Puzzoni, M.
    Giampieri, R.
    Mariani, S.
    Ziranu, P.
    Pusceddu, V.
    Donisi, C.
    Persano, M.
    Pinna, G.
    Cimbro, E.
    Parrino, A.
    Pretta, A.
    Lai, E.
    Liscia, N.
    Lupi, A.
    Giglio, E.
    Palomba, G.
    Casula, M.
    Pisano, M.
    Palmieri, G.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S543 - S544
  • [29] Telomere length: A novel biomarker for anti-EGFR therapy in colorectal cancer
    Augustine, Titto A.
    Baig, Mahadi A.
    Mariadason, John M.
    Maitra, Radhashree
    Goel, Sanjay
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
    Di Fiore, F.
    Sesbouee, R.
    Michel, P.
    Sabourin, J. C.
    Frebourg, T.
    BRITISH JOURNAL OF CANCER, 2010, 103 (12) : 1765 - 1772
12345